Breakthroughs, discoveries, and DIY tips sent six days a week. Terms of Service and Privacy Policy. Who doesn’t love a good math holiday? Most people know about Pi ...
Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...
The last time I wrote about Recursion Pharmaceuticals (RXRX), it was with respect to a Seeking Alpha article entitled "Recursion: CDK7 Differentiation Is Initially Paying Off." With respect to this ...
This page contains references to products from one of our advertisers. We may receive compensation when you click on links to those products. Terms apply to the offers listed on this page. For an ...
Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...
Is the S&P 500 index’s recent rally real, or is it just a bear-market bounce? That’s always a question investors have when the market is rising after a significant selloff. Given all the uncertainty ...
Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...
James is a published author with multiple pop-history and science books to his name. He specializes in history, space, strange science, and anything out of the ordinary.View full profile James is a ...
Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results